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SUMMARY
The pro-longevity enzyme SIRT6 regulates various metabolic pathways. Gene expression analyses 
in SIRT6 heterozygotic mice identify significant decreases in PPARα signaling, known to regulate 
multiple metabolic pathways. SIRT6 binds PPARα and its response element within promoter 
regions and activates gene transcription. Sirt6+/− results in significantly reduced PPARα-induced 
β-oxidation and its metabolites and reduced alanine and lactate levels, while inducing pyruvate 
oxidation. Reciprocally, starved SIRT6 transgenic mice show increased pyruvate, acetylcarnitine, 
and glycerol levels and significantly induce β-oxidation genes in a PPARα-dependent manner. 
Furthermore, SIRT6 mediates PPARα inhibition of SREBP-dependent cholesterol and triglyceride 
synthesis. Mechanistically, SIRT6 binds PPARα coactivator NCOA2 and decreases liver NCOA2 
K780 acetylation, which stimulates its activation of PPARα in a SIRT6-dependent manner. These 
coordinated SIRT6 activities lead to regulation of whole-body respiratory exchange ratio and liver 
fat content, revealing the interactions whereby SIRT6 synchronizes various metabolic pathways, 
and suggest a mechanism by which SIRT6 maintains healthy liver.
Graphical Abstract
In Brief
How the pro-longevity enzyme SIRT6 coordinates between various metabolic pathways is still 
obscure. Here, Naiman et al. show that SIRT6 activates PPARα to promote fatty acid beta 
oxidation and inhibit pyruvate oxidation during fasting. This ultimately decides the energy source 
under nutrient-limited conditions, promoting fat usage over other energy sources.
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INTRODUCTION
Metabolic diseases such as obesity, type 2 diabetes, and fatty liver are becoming the 
epidemic of the twenty-first century. Their influence on society, in terms of public health and 
their economic cost, is enormous. The worldwide increase in lifespan is associated with a 
corresponding rise in obesity-related pathologies. Thus, increasing our understanding of key 
regulators that play a role in healthy lifespan is crucial. Sirtuins are a family of NAD+-
dependent deacylases homologous to yeast SIR2 deacetylase (Imai et al., 2000), which were 
shown to regulate lifespan and age-related metabolic diseases (Tissenbaum and Guarente, 
2001; Whitaker et al., 2013).
Of the seven mammalian sirtuins, SIRT6 was shown to regulate longevity (Kanfi et al., 
2012) and various physiological pathways (Zhong et al., 2010). These include embryonic 
development, DNA repair, transposon stability, metabolism of carbohydrates, cholesterol 
and fat, inflammation, circadian rhythms, cancer, and aging (Kuang et al., 2018). SIRT6 
deficiency in primates or its inactivating mutation in human causes peri- and post-embryonic 
lethality, respectively (Ferrer et al., 2018; Zhang et al., 2018), while transgenic (TG) mice 
overexpressing SIRT6 have an increased male lifespan (Kanfi et al., 2012). Furthermore, in 
old age these mice are less susceptible to a spectrum of aging-related dysfunctions 
(Roichman et al., 2017). Similarly, calorie restriction (CR), known to extend healthy lifespan 
in both murine and primate models, increases SIRT6 levels (Kanfi et al., 2008a). This 
suggests that SIRT6 might mediate the beneficial effects of CR, resulting in increased 
lifespan. Indeed, male SIRT6 TG mice have a liver transcription profile highly similar to 
male mice under CR (Kanfi et al., 2012). Thus, SIRT6 is a key regulator of healthy aging, 
via its effects on metabolism.
SIRT6 is involved in many facets of metabolism, regulating key metabolic pathways such as 
insulin-like growth factor (IGF-1) (Sundaresan et al., 2012) and AMP-activated protein 
kinase (AMPK) (Cui et al., 2017). Glucose metabolism is also controlled by SIRT6 via 
inhibition of HIF1α-dependent transcription including glucose transporter genes, 
subsequently reducing glycolysis (Zhong et al., 2010). Interestingly, SIRT6 was also found 
to negatively regulate gluconeogenesis in the liver by regulating PGC1α and FOXO1 
activities (Dominy et al., 2012; Zhang et al., 2014). SIRT6 is also an important regulator of 
lipid homeostasis. SIRT6 inhibits cholesterol and triglyceride biosynthesis by inhibiting 
SREBP1/2, and controls hepatic fat metabolism by repressing miR122 (Elhanati et al., 2013, 
2016). SIRT6 TG mice are protected against the physiological damages of a high-fat diet 
(HFD) (Kanfi et al., 2010), whereas fat-specific SIRT6 knockout (KO) increases obesity-
related phenotypes (Kuang et al., 2017; Xiong et al., 2017). Liver-specific KO of SIRT6 
results in increased hepatic steatosis and decreased β-oxidation (Kim et al., 2010). In 
contrast, SIRT6 TG mice fed an HFD have decreased micro-vesicular lipidosis and reduced 
body fat content compared to their wild-type (WT) littermates (Kanfi et al., 2010). Despite 
such extensive studies of SIRT6, our knowledge of its involvement in specific metabolic 
pathways, particularly β-oxidation, is still limited. Moreover, how SIRT6 coordinates 
between these various metabolic pathways is unknown.
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PPARα, one of the three peroxisome proliferator-activated receptor (PPAR) isoforms, is a 
key transcription factor in hepatic β-oxidation. PPARα binds to a diverse group of 
compounds, such as WY 14,643 (WY) (Kersten, 2014), and to DNA as a mostly obligatory 
heterodimer with retinoic acid receptor RXRα, recognizing the PPAR response elements 
(PPREs). PPARα can be found in many large complexes and its ligand binding induces 
conformational changes, allowing coactivators to directly bind to PPARα, mainly via the 
LXXLL motif (Bugge and Mandrup, 2010). The known PPAR coactivator SRC2/NCOA2 
binds PPARs and its main function is the recruitment of histone acetyltransferases (HATs), 
such as P300 and CBP (Powell et al., 2007). These HATs acetylate the chromatin 
surrounding the PPRE and activate PPARα-dependent transcription.
PPARα is expressed mainly in tissues with a high capacity for fatty acid oxidation, primarily 
the liver and heart (Moreno et al., 2010). Under conditions that demand fatty acids oxidation 
such as fasting, PPARα ensures energy availability by upregulating the expression of 
enzymes necessary for fat oxidation, such as CPT1α (Leone et al., 1999; Mandard et al., 
2004). CR was shown to increase hepatic PPARα-mediated fatty acid oxidation and whole-
body fat oxidation rates (Takemori et al., 2011). Once activated, PPARα promotes β-
oxidation of fatty acids, releasing free fatty acids, thereby increasing acetyl-coA production 
from fats. Aside from its direct role in β-oxidation, PPARα also indirectly drives the liver 
toward lipid oxidation by inhibiting glycolysis-derived pyruvate oxidation via PDK4 
activation, and by increasing gluconeogenic precursors such as lactate and alanine (Baes and 
Peeters, 2010). Additionally, PPARα was shown to inhibit SREBP-mediated cholesterol and 
triglyceride synthesis (König et al., 2007, 2009). Thus, PPARα also regulates β-oxidation 
indirectly via several modes of regulation, including activation of gluconeogenesis and 
inhibition of pyruvate oxidation and cholesterol/triglyceride synthesis.
PPARα shares several properties with SIRT6. Both were implicated in hepatic β-oxidation, 
inflammation, and circadian clock regulation (Chen and Yang, 2014; Vachharajani et al., 
2016), and their activities increase under starvation and CR. SIRT6 and PPARα KO mice 
have shortened lifespans, and their levels decrease in aged mice (Howroyd et al., 2004; 
Kaluski et al., 2017; Mostoslavsky et al., 2006). Thus, these findings suggest that a 
coregulatory interaction between SIRT6 and PPARα may exist. Here, we underscore the 
interplay between SIRT6 and PPARα and demonstrate how SIRT6 coordinates different 
metabolic pathways.
RESULTS
SIRT6 Deficiency Inhibits PPARα Signaling Gene Expression
To identify the physiological pathways regulated by SIRT6, we performed quantitative 
transcriptome analysis based on RNA sequencing (RNA-seq) from livers of WT and SIRT6 
heterozygotic (HZ) mice (Table S1A). The top highly differentially expressed (DE) genes 
(Figure 1A) were validated by quantitative real-time PCR (Figure 1B; Table S1B). 
Interestingly, the top three pathways differentially regulated in SIRT6 HZ mice are all 
directly related to β-oxidation. Ingenuity pathway analysis (IPA) (Krämer et al., 2014) 
identified Acyl-CoA hydrolysis, an intermediate step in β-oxidation, as the most 
significantly regulated pathway. The second-ranked pathway was triacylglycerol 
Naiman et al. Page 4
Cell Rep. Author manuscript; available in PMC 2020 April 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
degradation, which hydrolyzes triacylglycerol into fatty acids, used in β-oxidation. The third 
pathway, stearate biosynthesis, involves saturated fatty acid synthesis from palmitate and 
carbohydrates. Other pathways include Ehprin and VEGF signaling, involved in 
differentiation and angiogenesis, respectively (Figure 1C). Consistent with these findings, 
PPARα, a key regulator of liver fatty acid β-oxidation was identified as the most 
significantly inhibited upstream regulator of the DE genes. Likewise, PPARγ was identified 
as a significantly inhibited regulator. Other regulators include TNFα, a known SIRT6 target 
of inflammation, and ACOX1 and EHHADH, which, similar to PPARα, regulate β-
oxidation (Figure 1D). These findings strongly suggest that SIRT6 activates PPARα.
Indeed, many genes activated by PPARα were inhibited in HZ mice, whereas genes 
inhibited by PPARα were activated in HZ mice (Figure 1E). Likewise, lipid metabolism, the 
primary pathway of PPARα, was a top network found in the DE genes. Both SIRT6 and 
PPARα are centrally placed in the lipid metabolism network, indicating possible 
coordination between both proteins in regulating fat metabolism (Figure 1F). Other known 
SIRT6-regulated networks such as inflammation and carbohydrate metabolism were 
identified as well (Figure S1). Furthermore, comparison of HZ liver DE genes to all 
microarrays currently in the GEO database using the ExpressionBlast tool (Zinman et al., 
2013) identified the top three highly significant matches to be PPARα KO microarrays 
(Figure 1G). Moreover, 7 of the top 20 matches were from PPARα KO experiments (Table 
S2). This shows that SIRT6 HZ mice display a gene expression profile most similar to 
PPARα KO mice, compared to all other existing microarray expression profiles. Aside from 
PPARα, SIRT6 HZ expression data were similar to known SIRT6-regulated pathways such 
as infection and cancer (Lerrer et al., 2016; Table S2). Altogether, these findings identified 
PPARα as a candidate SIRT6-regulated pathway.
SIRT6 Directly Interacts with PPARα and Binds to and Activates the PPRE In Vivo
To investigate the mechanism underlying SIRT6 activation of PPARα signaling, PPARα 
levels and acetylation were examined in WT and HZ mice. PPARα mRNA and protein 
levels were similar in WT and HZ mice (Figures S2A and S2B). In addition, in line with 
previous studies (Oka et al., 2011), no acetylation was detected on PPARα (Figure S2C). 
Next, we examined whether SIRT6 and PPARα might physically interact. Recombinant 
PPARα-GST tagged protein co-immunoprecipitated with recombinant SIRT6-FLAG-tagged 
protein, but not with FLAG-tagged BIP used as a negative control. Additionally, GST 
protein alone did not co-immunoprecipitate with SIRT6 (Figure 2A). These findings show 
that SIRT6 specifically binds PPARα in vitro. The binding affinity of SIRT6 to PPARα in 
comparison to other known SIRT6 interactors was then measured. A microfluidics protein 
binding platform (Ben-Ari et al., 2013) was used to quantify SIRT6 binding affinity to 
selected proteins. Binding was measured as fluorescent signals of interactors normalized to 
SIRT6 levels. Interestingly, in comparison to two known SIRT6 interacting proteins, HIF1α 
and CTIP, the binding affinity of SIRT6 to PPARα was significantly higher than to HIF1α, 
suggesting strong interaction between PPARα and SIRT6 (Figure 2B). A representative 
binding signal is shown (Figure 2B, right panel). We then examined SIRT6 binding to 
PPARα in HEK293T cells. As seen in Figure 2C, PPARα-GFP specifically co-
immunoprecipitated with SIRT6-FLAG but not with GFP negative control. Reciprocally, 
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endogenous SIRT6 specifically co-immunoprecipitated with PPARα-FLAG (Figure 2D). In 
all the binding experiments using intact cells, the binding was not DNA dependent, as 
ethidium bromide did not abolish the interaction (Figures 2C and 2D). Endogenous SIRT6 
and GFP-tagged PPARα or endogenous PPARα and FLAG-SIRT6 interactions were shown 
in mouse Hepa1–6 hepatocytes as well (Figure S2D). These results show that SIRT6 and 
PPARα directly interact and are present in common protein complexes in cells.
We demonstrated that SIRT6 and PPARα associate with one another. Thus, the direct 
binding of SIRT6 to the PPARα-binding DNA element-PPRE and whether PPARα is 
required for this interaction were examined by using the quantitative protein interacting 
DNA (QPID) microfluidics method (Glick et al., 2016b). Recombinant SIRT6-FLAG was 
immobilized to the chip surface and incubated with Cy5-labeled PPREx3 or mutant DNA 
sequences (Oka et al., 2012) in the presence or absence of recombinant free Myc-tagged 
PPARα. The interaction ratio was calculated and is shown in Figure 2E. Importantly, 
significant and strong SIRT6 binding to PPRE was found specifically in the presence of 
PPARα. In contrast, SIRT6 did not bind to a mutant motif regardless of the presence of 
PPARα. A representative binding experiment is shown (Figure 2E). SIRT6’s interaction with 
the PPRE was also examined in the presence or absence of PPARα using serial DNA 
dilutions (Glick et al., 2016b). In the presence of PPARα, SIRT6 displayed a logarithmic 
binding curve that reached saturation, indicating marked affinity to the PPRE but not to 
mutant PPRE sequence, whereas SIRT6 alone displays a non-specific linear binding curve 
similar to the PPRE mutant (Glick et al., 2016b; Figures S3A and S3B). These findings 
show that SIRT6 binds specifically to the PPRE in a PPARα-dependent manner.
Next, we examined whether SIRT6 can activate the PPRE in vivo using a luciferase reporter 
assay. A construct containing the luciferase gene fused to three tandem repeats of the PPRE 
(Kim et al., 1998) was transfected into mouse Aml-12 hepatocyte cells along with SIRT6 or 
control plasmids. SIRT6 overexpression significantly induced the luciferase signal (Figure 
S3C). Importantly, SIRT6 does not activate negative control promoter sequences (Figure 
S3D). Thus, SIRT6 stimulates endogenous PPARα-dependent promoter activity in liver 
cells. To examine whether SIRT6 catalytic activity is required for PPARα transactivation, 
HEK293T cells were transfected with either SIRT6 or a catalytically inactive mutant, SIRT6 
H133Y. Notably, SIRT6 but not the SIRT6 catalytic mutant activated PPRE transcriptional 
activity (Figure 2F). These findings suggest that SIRT6 enzymatic activity is required to 
activate the PPRE. Moreover, induction of the PPRE by PPARα overexpression was further 
increased in SIRT6 overexpressing cells (Figure 2G). Thus, the two proteins may work 
cooperatively to activate the PPRE. These data indicate that SIRT6 directly activates the 
PPRE via PPARα.
Subsequently, SIRT6 binding to the PPRE within promoters of PPARα target genes in vivo 
was measured using chromatin immunoprecipitation (ChIP) assay in primary hepatocytes. 
As shown in Figure 2H, in comparison to immunoglobulin G (IgG) control, endogenous 
SIRT6 significantly binds to the PPREs of several PPARα target genes. Strikingly, SIRT6 
binds to the PPREs of Cpt1α, the rate-limiting enzyme of β-oxidation, as well as to the 
positive control Srebp2 promoter (Elhanati et al., 2013). This binding was specific, as SIRT6 
does not bind to a negative control DNA sequence in the GAPDH gene promoter (Figure 
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2H). Srebp2 promoter was shown to be inhibited and deacetylated on H3K9 by SIRT6 (Tao 
et al., 2013). Indeed, in comparison to WT livers, Sirt6+/− livers showed significant 
increased Srebp2 promoter H3K9 acetylation levels. In contrast, specifically on the SIRT6-
bound PPREs, Sirt6+/− livers showed significantly decreased H3K9 acetylation levels. 
(Figure 2I). Notably, SIRT6 binds not only to PPREs within promoters but also to the PPRE 
localized 4 Kb distal of Angptl4 (Figures 2H and S3E). These findings further indicate that 
SIRT6 binding is PPREs specific and not due to its proximity to other transcription elements 
near the promoter region. Moreover, these findings suggest that SIRT6 deacetylase activity 
promotes the activation of PPREs potentially via deacetylation of a PPARα cofactor and not 
via deacetylation of PPARα or the PPRE.
SIRT6 was shown to bind to PPARα and PPREs under normal growth conditions (Figure 2). 
Next, we examined whether SIRT6 binding to PPRE depends on PPARα activity. Primary 
hepatocytes were treated with the specific PPARα agonist, WY to induce PPARα activity. 
Interestingly, treatment with WY did not further increase SIRT6 binding to PPREs in 
comparison to untreated controls (Figure S3F). These findings imply that the in vivo 
association between SIRT6 and the PPRE is constant, irrespective of PPARα activation. 
Taken together, these results conclusively show that SIRT6 binds to and activates the PPRE 
in vivo in a PPARα-dependent manner.
SIRT6 Stimulates WY-Induced PPARα Transcriptional Activity In Vivo
As SIRT6 was found to bind to the PPRE (Figure 2), the effect of SIRT6 on transcription of 
various hepatic PPARα signaling pathways was investigated. Gene expression of PPARα-
regulated pathways was examined in WT or SIRT6 HZ primary hepatocytes treated with 
WY. As previously demonstrated, upon WY treatment a strong induction of PPARα 
transcription was observed both in mouse liver and primary hepatocytes relative to controls 
(Szalowska et al., 2014; Figure 3). These pathways include mitochondrial β-oxidation, 
peroxisomal β-oxidation, acyl-CoA binding/hydrolysis, lipid storage/transport, and 
ketogenesis. WY does not directly bind to SIRT6, nor does it affect SIRT6 deacylase activity 
or RNA levels (Figures S3A–S3C). Importantly, SIRT6 HZ primary hepatocytes consistently 
displayed reduced PPARα activation (Figure 3A). Conversely, in comparison to WT, SIRT6 
TG mice had significantly increased induction of PPARα targets (Figure 3B) in primary 
hepatocytes. These findings show that SIRT6 uniformly promotes PPARα transcriptional 
activity in multiple pathways in primary liver cells.
Next, in order to examine whether SIRT6 can activate PPARα in vivo, SIRT6 HZ and TG 
mice along with their appropriate WT controls were treated with WY. Consistent with the 
response of primary hepatocytes, SIRT6 HZ mice displayed significantly reduced PPARα 
activation (Figure 3C). Additionally, SIRT6 TG mice had significantly increased PPARα 
activation (Figure 3D). SIRT6 was previously shown to regulate β-oxidation via AMPK (Cui 
et al., 2017; Elhanati et al., 2016). Yet, WY is a specific PPARα activator, and no changes in 
phosphorylated AMPK were found following this treatment (Figure S4D). These results 
show that SIRT6 activates PPARα signaling in livers in vivo. Interestingly, as previously 
shown in mice but not in primary hepatocytes, the lipid transport gene Slc27a1 is induced by 
WY treatment (Rakhshandehroo et al., 2010), and SIRT6 further activated this gene in mice 
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(Figures 3C and 3D). In addition, SIRT6 also increases the expression of Fgf21 longevity 
hepatokine, a critical factor for PPARα activity (Figure 3; Goto et al., 2017). This indicates 
that in vivo, SIRT6 may have a broader effect in regulating PPARα signaling. Altogether, 
these results show that SIRT6 specifically activates PPARα-dependent transcription of 
several metabolic pathways.
SIRT6 Deficiency Inhibits PPARα-Regulated Metabolic Pathways
SIRT6 activates the PPARα-dependent transcription of genes involved in several metabolic 
pathways (Figure 3). Thus, we examined the downstream effects of SIRT6 on a range of 
PPARα-regulated pathways. Specifically, we investigated the ability of SIRT6 to activate 
PPARα pathways β-oxidation, gluconeogenesis, and glycerol transport, and to inhibit 
glycogenolysis and pyruvate metabolism, in WY treated mice. When activated, in order to 
increase β-oxidation, PPARα inhibits pyruvate oxidation by upregulating PDK4 and 
increases fatty acid and glycerol transport. PPARα also increases precursors of 
gluconeogenesis such as lactate and alanine (Baes and Peeters, 2010; Figure 4A).
First, regulation of pyruvate oxidation by SIRT6 was examined. PKD4 kinase and its 
substrate PDC (P-PDC) are strongly induced in mouse livers following WY treatment 
(Figure 4B, left panel). Both PDK4 and P-PDC protein levels were significantly lower in HZ 
mice, while total PDC levels remained unchanged. This indicates that SIRT6 deficiency 
reduces PPARα-dependent inhibition of pyruvate oxidation (Figure 4B, middle and right 
panels). We next measured the regulation of fatty acid transport and β-oxidation. RNA levels 
of fatty acid transporter Cd36 were strongly induced following WY treatment and were 
significantly less activated in HZ mice (Figure 4C, left panel). Moreover, β-oxidation 
products were measured from labeled palmitate ex vivo in liver mitochondria. 
Acetylcarnitine metabolite levels, the product of long-chain fatty acid oxidation, were 
significantly reduced in SIRT6 HZ mice after WY treatment compared to controls (Figure 
4C, middle panel). Likewise, significantly lower levels of the final product, palmitate-
derived CO2, generated by the Krebs cycle from labeled palmitate, were found in isolated 
hepatic mitochondria from WY-treated HZ livers (Figure 4C, right panel). Thus, SIRT6 HZ 
mice have decreased β-oxidation compared to control mice upon WY treatment. These 
results support a role for SIRT6 in promoting PPARα-mediated β-oxidation.
PPARα is also known to increase gluconeogenic precursors glycerol, lactate, and alanine. 
Thus, we first measured RNA levels of the glycerol transporter Aqp3 in the liver. As can be 
seen in Figure 4D, in comparison to WT littermates, upon WY treatment HZ mice showed 
significantly reduced induction of RNA levels of Aqp3. Likewise, the metabolites lactate and 
alanine were also significantly less induced in HZ mice in response to WY treatment (Figure 
4E). We subsequently measured RNA levels of key enzymes of glycogenolysis, Gys2 and 
Pygl. Similar to previous studies, WY treatment inhibited the expression of the 
glycogenolysis gene Pygl and activated the glycogen synthesis gene Gys2. This effect was 
nearly completely abolished in HZ mice (Figure 4F). These data demonstrate that SIRT6 
activates a broad spectrum of PPARα signaling pathways to regulate metabolism, ultimately 
increasing β-oxidation.
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Next, we aimed to examine whether the effects of SIRT6 on gene expression and metabolites 
are also found under normal physiological conditions in which PPARα is active. PPARα is 
known to be important for activating hepatic β-oxidation and inhibiting pyruvate oxidation 
in response to fasting. Thus, we examined whether SIRT6 TG mice have any defects in these 
fasting-regulated pathways. Indeed, as can be seen in Figure 4G, under fasting conditions, 
SIRT6 overexpression results in a significant increase in pyruvate levels, a sign of inhibited 
pyruvate oxidation, and an increase in β-oxidation metabolite acetylcarnitine (Figure 4G). In 
addition, a significant increase in glycerol levels was found in TG mice under starvation. 
These changes in metabolites were correlated with a significant increase in the transcription 
of the pyruvate oxidation inhibitor Pdk4 and the β-oxidation activators Cpt1a, Acot3, and 
Ehhadh genes and Gos2, a lipid storage gene, were found (Figure 4H). Altogether, these data 
show that SIRT6 activates PPARα, leading to decreased pyruvate oxidation, increased β-
oxidation, and increased uptake of gluconeogenic precursors, as found under a normal 
fasting response.
SIRT6’s Regulation of Pyruvate and β-oxidation Is PPARα Dependent
To show a PPARα dependency in the effect of SIRT6 on PPARα signaling, the following 
experiment was performed: PPARα was knocked down (KD) using two different small 
interfering RNAs (siRNAs) in both primary and Hepa1–6 hepatocytes overexpressing 
SIRT6. PPARα KD was validated in both RNA and protein levels (Figures 5A and S5A–
S5C). First, we examined to what extent SIRT6 can stimulate PPRE luciferase reporter when 
PPARα is depleted. As seen in Figure 5B, in comparison to control scrambled siRNA, 
SIRT6 activation of PPRE was abolished in PPARα KD Hepa1–6 cells. The importance of 
PPARα in mediating SIRT6’s effect on β-oxidation genes was investigated as well. Indeed, 
SIRT6 activation of β-oxidation genes was significantly reduced in PPARα KD primary 
hepatocytes (Figure 5C). Only two genes were found to be not wholly PPARα dependent 
(Figures S5D and S5E). Lastly, in comparison to control cells, the effect of SIRT6 on 
pyruvate signaling was also significantly inhibited in PPARα KD primary hepatocytes 
(Figures 5D and S5F). Altogether, these data conclusively show that PPARα mediates the 
effect of SIRT6 on multiple PPARα signaling pathways.
SIRT6 Increases Hepatic Fat Loss and Improves RER via PPARα in Response to WY
Finally, we further explored the broader effects of activation of PPARα by SIRT6. RNA-seq 
was performed from livers of WT and SIRT6 HZ mice treated with WY (Figure 6A; Table 
S1, tabs C and D). In line with the abovementioned results, PPARα was found to be one of 
the most strongly inhibited regulators in HZ mice (Figure 6B). Previous studies showed that 
induction of PPARα strongly represses SREBP1/2-mediated transcription (Zhang et al., 
2015). Indeed, SREBP1/2 was among the most highly activated regulators found in HZ mice 
under WY treatment (Figure 6B). Importantly, this effect was not observed under normal 
conditions, in the absence of WY (Figure 1), suggesting that the effect of SIRT6 
haploinsufficiency on the SREBP pathway is PPARα dependent. Moreover, under normal 
conditions, in contrast to SIRT6 KO (Tao et al., 2013), SIRT6 HZ mice have similar SREBP 
levels as WT mice (Figure S4D). Further pathway analysis showed that the top-five 
pathways differentially expressed in SIRT6 HZ mice were activation of SREBP-regulated 
pathways, cholesterol and sterol biosynthesis, and activation of inflammation-related 
Naiman et al. Page 9
Cell Rep. Author manuscript; available in PMC 2020 April 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
pathways, B cell development, and antigen presentation (Figure 6C). Network analysis 
showed that the top significant network in the WY-treated hepatic transcriptome placed 
PPARα, SREBP, and TNFα/NFKb as central nodes (Figure S6). This indicates a broad and 
integrative role for SIRT6 in inflammation, cholesterol synthesis, and β-oxidation in a 
PPARα-dependent manner.
Next, we examined the overlap between PPARα-dependent genes and known SREBP targets 
in HZ DE genes. Notably, SIRT6 DE genes activated by SREBP1/2 are inhibited by PPARα, 
showing an opposite regulation (Figure 6D). These genes are involved in triglyceride and 
cholesterol synthesis. Importantly, as seen in Figure 6F, in the absence of PPARα activation, 
SIRT6 did not affect these genes in HZ mice. Yet, upon WY treatment, SIRT6 
haploinsufficiency significantly blunted PPARα inhibition of SREBP-dependent genes 
(Figure 6E). Thus, these findings show that SIRT6 regulates PPARα inhibition of SREBP-
dependent cholesterol synthesis.
We then examined the physiological effect of the SIRT6 regulation of PPARα-mediated 
inhibition of SREBP. Hepatic lipid content is composed of triglycerides and cholesterol, 
regulated by SREBP-1 and −2, respectively (Xu et al., 2013). Therefore, we treated mice 
with WY and analyzed whole-liver fat content using NMR. WY treatment significantly 
decreased fat content in liver by almost 50%. Strikingly, in SIRT6 TG mice, this fat 
reduction was significantly enhanced (Figure 6F). Likewise, in HZ mice this fat reduction 
was significantly inhibited (Figure 6G). In addition, we examined the cumulative 
physiological outcome of these metabolic changes. Respiratory exchange ratio (RER) was 
quantified in WY treatment in WT and HZ mice. The RER ratio under a normal diet was 
similar between WT and HZ mice. Daily WY administration caused a decrease in RER 
shortly after WY supplementation in WT mice (Figure 6H). Strikingly, the HZ mice had a 
significantly weaker response to WY treatment, indicating reduced β-oxidation. In addition, 
once the WY treatment was stopped, the RER returned to normal, and the changes 
previously seen between WT and HZ disappeared (Figure 6H). These findings suggest that 
SIRT6 directs the energy source utilization toward fat under broader conditions requiring 
PPARα activation.
SIRT6 Regulates PPARα Activity via NCOA2 K780 Deacetylation
SIRT6 deacetylase activates PPARα, yet no acetylation was detected on PPARα (Figure 
S2C). In addition, previously SIRT6 was reported as a histone deacetylase, which usually 
results in reduced levels of transcription. Intriguingly, here, SIRT6 induces PPRE H3 K9 
acetylation and activity (Figure 2). Therefore, we examined whether the mechanism 
underlying SIRT6’s activation of PPARα is potentially via the deacetylation of one of its 
coactivators or corepressors. The acetylation levels of 12 PPARα coactivators or 
corepressors were compared between WT and SIRT6 TG livers using stable isotope labeling 
by amino acids in cell culture (SILAC) mass spectrometry (MS) analyses. Within these, only 
one protein, NCOA2, a known PPARα coactivator, showed significantly lower differentially 
acetylated levels on K780 in TG mice (Figure 7A). Therefore, SIRT6 and NCOA2 
interaction was examined. As seen in Figure 7B, endogenous SIRT6 interacts with FLAG-
tagged NCOA2. Conversely, endogenous NCOA2 interacts with FLAG-tagged SIRT6. This 
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suggests that NCOA2 might be the PPARα coactivator through which SIRT6 mediates the 
induction of PPARα activity.
To explore the role of NCOA2 acetylation in PPARα activation, NCOA2 K780 was mutated 
into arginine (K780R) or glutamine (K780Q), mimicking constitutive deacetylated or 
acetylated lysine, respectively. PPRE-luciferase activity was measured in HEK293T cells 
overexpressing WT, K780R, or K780Q with or without overexpression of SIRT6, PPARα, or 
both. As previously published, NCOA2 significantly induced PPRE activity (Røst et al., 
2009). Notably, in comparison to WT or K780Q, the K780R mutant significantly further 
increases PPRE activation (Figures 7C and S7A). WT and K780Q showed similar levels of 
PPRE activation, suggesting that NCOA is highly acetylated and its deacetylation is required 
for further PPRE activation. Strikingly, indeed, SIRT6 overexpression significantly induced 
WT NCOA2-dependent PPRE activation to the same levels as K780R, the deacetylated 
NCOA2 mimicker. Moreover, SIRT6 overexpression had no effect on either K780Q- or 
K780R-induced PPRE activity or on NCOA2-PPARα association (Figures 7C and S7B). 
These findings suggest a model in which SIRT6 promotes PPARα activity via NCOA2 K780 
deacetylation, which leads to increased HAT acetylation of PPRE chromatin and subsequent 
activation of PPARα-dependent signaling (Figure 7D).
DISCUSSION
Here, we show that SIRT6 regulates hepatic β-oxidation by activating PPARα via NCOA2 
deacetylation. This regulation culminates in a PPARα-dependent maintenance of normal 
whole-body RER and improved liver fat content. These findings significantly contribute to 
our understanding of how SIRT6 coordinates central metabolic pathways in response to 
energy fluctuations.
Previously, we showed that SIRT6 overexpression mimics key aspects of the rodent CR 
response (Kanfi et al., 2012). β-oxidation is a known hallmark of CR in both rodents and 
monkeys (Bruss et al., 2010; Rhoads et al., 2018). Remarkably, SIRT6 activation of PPARα 
also increases fatty acid degradation and peroxisomal β-oxidation, revealing an additional 
similarity to the CR response. Moreover, both SIRT6 and PPARα levels increase under 
starvation and CR (Masternak and Bartke, 2007). Altogether, in parallel to increased PPARα 
levels, we suggest here a pathway of PPARα regulation under CR by induction of its activity 
via SIRT6.
What are the physiological outcomes of this PPARα induction by SIRT6? A significant 
amount of data show a role for SIRT6 as a guardian of healthy liver (Kim et al., 2010). HFD 
or liver-specific deletion of SIRT6 in mice causes fatty liver formation while SIRT6 
overexpression significantly reduced fatty liver incidence (Kanfi et al., 2010). Thus, 
potentially SIRT6 protects against hepatic steatosis through PPARα activation and the 
increase in fatty acid β-oxidation. In addition, liver-specific SIRT6 KO impairs hepatic 
ketogenesis via induced Fsp27β. When fed a ketogenic diet, these mice also showed 
exacerbated hepatic steatosis and inflammation (Chen et al., 2019). This adds another 
interesting layer for SIRT6’s protective effect on liver pathologies. Yet, it is possible that 
SIRT6 expression in other tissues also contributes to this and other liver phenotypes 
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observed in the current study due to the use of a whole-body HZ model. However, samples 
from human patients with fatty liver or liver fibrosis exhibited significantly lower levels of 
SIRT6 than did normal controls (Ka et al., 2017; Kim et al., 2010). Thus, SIRT6 activation 
has great therapeutic potential in treating fatty liver diseases.
SIRT6 possesses histone deacetylase activity that is usually associated with repressed 
transcription. Here, we show an example of direct activation of gene transcription by SIRT6. 
SIRT6 binds to PPARα and its PPREs in a PPARα-dependent manner, inducing PPARα-
mediated transcription. Importantly, SIRT6 enzymatic activity is required for this induction. 
Therefore, here, we aimed to identify the precise target for SIRT6 within the PPARα 
complex on the PPRE. There are at least three possible options. First, SIRT6 might directly 
affect PPARα, either by deac(et)ylation, or mono-ADP-ribosylation (monoADPR). Yet, we 
and others were unable to detect acetylation on PPARα (Figure S2C; Oka et al., 2011). 
However, this possibility cannot be rigorously excluded at this stage. A second possibility is 
that SIRT6 binding to PPARα results in a conformational change, allowing increased 
binding or recruitment of PPARα coactivators. In support of this model, SIRT6 contains the 
well-known LXXLL motif (Figure S7C) in its coactivator domain, a motif commonly found 
in PPARα-binding coactivators. Yet, given that SIRT6 enzymatic activity is required for 
PPARα activation, such a model does not fully explain the activity of SIRT6 on PPARα. 
Thus, a final, more comprehensive model suggests that SIRT6 activates PPARα via 
deacetylation and activation of a member of the PPARα complex, such as a coactivator 
acetyltransferase. Indeed, we found that SIRT6 regulates PPARα activity via NCOA2 K780 
deacetylation. In analogy, SIRT1 was shown to activate PPARα indirectly via deacetylation 
and activation of its coactivator, PCG1α (Purushotham et al., 2009). Furthermore, in 
contrast, SIRT4 was shown to inhibit PPARα signaling and β-oxidation indirectly by 
inhibiting SIRT1 activity by NAD+ substrate competition (Laurent et al., 2013). While 
SIRT6 and SIRT1 increase in starvation, SIRT4 decreases in starvation, which may 
potentially explain their opposite roles in β-oxidation (Laurent et al., 2013; Kanfi et al., 
2008a, 2008b).
Deacetylation of NCOA2 K780 promotes its activation of PPARα. Likewise, NCOA2 
Ser736 phosphorylation is also known to augment PPAR activity via increased binding and 
recruitment of P300 acetyltransferase to NCOA2 and PPREs (Frigo et al., 2006). Thus, it 
would be interesting to further investigate the interaction between these posttranslational 
modifications on PPARα activation potentially by increased P300 recruitment. In support of 
this model, indeed, we found an inverse correlation between NCOA2 and H3K9 acetylation 
along with increased PPARα activation.
Regarding the involvement of PPARα in SIRT6-dependent phenotypes, an interesting 
question is the potential contribution of PPARα to the gender-specific effects found in 
SIRT6 TG mice. In mice, SIRT6 regulation of body and fat mass is more pronounced in 
males. In addition, the reduced lifespan in SIRT6-deficient mice is more severe in males 
(Peshti et al., 2017). Similarly, SIRT6 overexpression extends lifespan, mimics a DR-like 
transcription profile, and reduces IGF-1 signaling only in males (Kanfi et al., 2012). This 
gender-specific effect is maintained over the course of evolution, in both monkeys and 
humans (Naiman and Cohen, 2018). In SIRT6 KO monkeys, only females survive to birth, 
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and in humans, SIRT6 deficiency results in sex reversal in the male fetus (Ferrer et al., 2018; 
Zhang et al., 2018). Interestingly, the effects of PPARα are also gender-specific. PPARα 
activators decrease adiposity in male but not female animals fed HFD, and reduce total 
cholesterol and triglycerides only in males in normal diet (Yoon et al., 2002). Moreover, the 
response of β-oxidation gene expression to PPARα agonist is much stronger in male mice 
and ovariectomized females than in WT females, indicating the involvement of gonadal sex 
steroids (Yoon, 2010). Similarly, in humans, males but not females carrying a PPARα 
polymorphism demonstrated improved triglyceride levels in response to statin treatment 
(Khan et al., 2004). Therefore, PPARα and SIRT6 share several gender-specific effects, 
particularly in protecting against obesity and its physiological consequences. It would be of 
great interest in future research to explore whether PPARα is involved in other male-specific 
SIRT6-regulated pathways such as lifespan extension.
Interestingly, in comparison to their WT littermates, no significant physiological effects 
were observed in SIRT6 HZ mice under normal growth conditions. For example, no changes 
in body weight and composition, daily activity, RER, or food intake were detected. This 
suggests that SIRT6 haploinsufficiency retains sufficient activity under unstressed 
conditions, at least to adulthood. Yet, under conditions in which PPARα is activated, such as 
increased β-oxidation (i.e., under food limitation), both copies of active SIRT6 are required. 
Notably, gene transcription changes in PPARα genes were found in SIRT6 HZ even under 
normal conditions, but these were not phenotypically evident until PPARα was activated. 
This may indicate that SIRT6 primes transcription to respond quickly to energy fluctuations 
such as changes in nutrient availability. We suggest that a certain minimum level of SIRT6 is 
necessary for long-term survival under fluctuating or chronic mild metabolic stress, such as 
that found in obese or old animals. Thus, SIRT6 may have therapeutic potential under 
chronic long-term stress conditions, for example, those that can be found in age-related 
diseases.
STAR⋆METHODS
Detailed methods are provided in the online version of this paper and include the following:
LEAD CONTACT AND MATERIALS AVAILABILITY
This study generated new unique plasmids. All unique plasmids generated in this study are 
available from the Lead Contact without restriction. Further information and requests for 
resources and reagents should be directed to and will be fulfilled by the lead contact, Prof. 
Haim Cohen (Haim.Cohen@biu.ac.il)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal Subjects—All animal procedures and use of mice were approved by the 
Institutional Animal Care and Use Committee of Bar Ilan University. Mice were housed on a 
12hr light/dark cycle at room temperature (22–24C) in the Bar Ilan animal facilities. Mice 
were maintained on standard rodent chow diet with ad libitum access to food and water. All 
mice used in these experiments were in good health. Mice were kept under specific pathogen 
free conditions in IVC cages that are routinely examined and found negative for viral 
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serology and both endo and ectoparasites. Male littermates were used for all experiments. 
Mice ranging from 12–15 months in age were randomly assigned to experimental groups. 
SIRT6 whole-body overexpressing (TG) mice were produced in CB6F1 strain, and 
maintained on a segregating stock containing equal contributions of C57BL/6J and BALB/
cOlaHsd (Harlan laboratories) backgrounds as previously described (Kanfi et al., 2010). 
SIRT6 whole-body heterozygote (HZ) 129SVJ mice were a kind gift from Mostoslavsky’s 
lab (Mostoslavsky et al., 2006).
Cell Culture—HEK293T, Hepa1–6 and Aml12 cells were obtained from ATCC. All cells 
were grown at 37C with 95% humidity and 5% CO2. Cells were tested for mycoplasma 
contamination (Mycoplasma PCR Detection Kit, Hylabs) and found negative. Cells were 
maintained in Dulbecco’s modified Eagle’s medium (GIBCO) supplemented with 10% FBS, 
1% penicillin, 1% streptomycin and 1% glutamine (Biological Industries).
Primary Cell Culture—Primary mouse hepatocytes were prepared as previously 
published (Lustig et al., 2011). Mice were sacrificed by CO2 and livers were immediately 
perfused for 7 minutes with warm (42°C) perfusion buffer (HBSSx1 [CellGro], NaHCO3 
2.1g/L, EDTA 0.2g/L, KCl 0.4g/L, Glucose 1g/L, pH = 7.4) at a constant rate of 4.5ml/min 
with a 25 g needle. Needles were threaded via the inferior vena cava and the portal vein was 
severed to allow drainage. This was followed by 10 minutes perfusion with warm (42°C) 
liver digest media (Invitrogen #17703–034). Livers were then extracted into 10cm sterile 
tissue culture plates in 10ml plating media (DMEM with FBS 10%, Sodium pyruvate 2mM, 
Pen/Strep 2%, Dexamethasone 1uM and Insulin 0.1uM). Livers were manually disrupted 
with scalpels and passed through a 10ml electronic pipette several times until a 
homogeneous mix was formed. Samples were then passed through a 70uM cell strainer 
(Corning) into a 50ml Falcon and centrifuged in swinging buckets at RT 50 g for 10min. 
Pelleted cells were then mixed with 10ml plating media and 10ml Percoll (GE Healthcare 
GE17-0891-01), and centrifuged again to separate hepatocytes. Hepatocytes were washed 
twice more with plating media and stained with Trypan Blue. 500,000 live cells were plated 
into collagen coated 6 well plates or 3 million live cells were plated on a 10cm plate in 
plating media for 6 hours. Media was then switched to maintenance media (10% FBS 4.5 
g/L glucose, 2 mM sodium pyruvate, 0.1 mM dexamethasone, and 1% penicillin/
streptomycin) overnight. All experiments were performed in maintenance media after 
overnight incubation, and cells were harvested within 24 hours of extraction.
METHOD DETAILS
WY Administration
In Vivo: Mice were gavaged with Wy 14,643 (AbMole) at a concentration of 50mg/kg 
dissolved in 0.5% Carboxymethylcellulose (Sigma). Control littermates were gavaged with 
only 0.5% Carboxymethylcellulose. WY mixture was sonicated briefly 10 s twice at low 
speed before use, and mixtures were prepared fresh before each daily gavage. 
Approximately 0.2ml solution was given to each mouse, depending on their specific weight 
(50mg/kg). Gavage was performed in the evening at 9 pm, and mice were sacrificed 9am for 
the 12 hour WY treatment. Mice were gavaged with water for one week prior to treatment to 
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accustom them to the procedure and monitored for signs of stress; food consumption, weight 
and overall health remained constant prior to the WY treatment.
In Vitro: Primary hepatocytes incubated overnight in maintenance media were treated the 
morning after hepatocyte extraction with 50uM WY freshly dissolved in DMSO for 12 
hours, with corresponding DMSO controls.
Cell Transfections
Aml12 and Hepa1–6 Cells: One day before transfection 300,000 cells were seeded onto 6 
well plates (Corning). Lipofectamene 2000 (Invitrogen) was used according to 
manufacturer’s protocol. 4ug total DNA was mixed with 10ul Lipofectamene in antibiotic-
free medium, incubated for 10 minutes, and dripped on cells. Media was changed 6 hours 
post-transfection. Cells were harvested 48 hours post transfection.
293T Cells: One day before transfection 200,000 or 2 million cells were seeded onto either 
6 well or 10cm plates (Corning), respectively. Calcium phosphate transfection protocol was 
used, with Hebsx2 buffer (NaCl 280mM, HEPES 50mM, 1.42 mM Na2HPO4·7H2O, pH = 
7.05). 14ug of total DNA for a 10cm, and 4ug total DNA for 6well plate were used. DNA 
was mixed with CaCl2 250mM, and gently dripped onto the Hebsx2 buffer over a vortex to 
produce bubbles. DNA and Hebs was incubated for 20 minutes. This mixture was then 
dripped onto cells. Medium was changed 6 hours post-transfection. Cells were harvested 48 
hours post-transfection.
Primary Hepatocytes: 400,000 cells were extracted and incubated overnight in 
maintenance media prior to transfection. Transfection was performed with RNAiMax and 
TriFECTA RNAi Kit according to manufacturer’s protocol. Medium was changed 24 hours 
post-transfection and cells was harvested 48 hours post-transfection.
DNA Constructs—For in vitro immunoprecipitation: SIRT6-Flag, PPARα-GFP and 
PPARα -FLAG were cloned from cDNA of 293T cells or mouse liver, for human or mouse 
constructs, respectively. pcDNA 3.1+or pCAGGS plasmids were used for mammalian cell 
expression. GFP was cloned from pEGFP and inserted into pcDNA- PPARα. For 
recombinant protein constructs: pET28a plasmid was used to add an N-terminal 6xHis tag to 
C-tagged Flag SIRT6 and BIP, and pGEX4t3 was used to add an N-terminal GST tag to 
GST- PPARα. For luciferase assays: SIRT6 H133Y mutant and Ncoa2 K780R and K780Q 
mutants were created using mutagenesis protocol using PFU Ultra II Fusion (Agilent) 
according to manufacturer’s protocol from pcDNA-SIRT6 or pcDNA-Ncoa2-Flag. PPREx3 
TK luciferase plasmid (Kim et al., 1998) was purchased from Addgene. pRL-TK renilla and 
pGL4 (hygro) luciferase was used (Promega).
Recombinant Protein Purification—Proteins were purified as previously published 
(Gil et al., 2013). pGEX4t3-GST-PPARα and pET28a-SIRT6/BIP-FLAG plasmids were 
transformed into bacteria BL21 (DE3) competent cells. A single positive colony from each 
plate was grown overnight at 37°C, 200RPM in 10ml LB, then diluted in the morning to 
400ml LB and incubated until O.D.600nm = 0.8. Bacteria were induced with 1mM IPTG for 
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3–4 hours at 37°C then washed with PBSx1 and resuspended in buffer A (50mM Sodium 
Phosphate Buffer pH 7.2, 50mM NaCl, 1mM β-mercaptoethanol) with mini EDTA-free 
protease inhibitor cocktail (Roche). Bacteria was homogenized using Dounce homogenizer 
and strained, then lysed with a microfluidizer (Microfluidics). 6xHis-tagged proteins were 
then incubated with Talon metal affinity resin (Clontech), and GST-conjugated proteins were 
incubated with GST-binding resin (Novagen) for 2 hours in 4°C with rotation, then resin was 
separated and washed. Elution for His tagged proteins was performed with 500mM 
imidazole, and 50mM reduced glutathione (Sigma) was used to elute GST-conjugated 
proteins. PD10 desalting columns (Amersham) were used for buffer exchange to purify 
recombinant proteins, which were then kept at −70°C in storage buffer ((30 mM Tris-HCl, 
pH 7.4, 50 mM NaCl, 1 mM DTT, 10% Glycerol).
Quantitative Real-Time PCR—Total RNA was extracted using Trizol (Sigma) according 
to manufacturer’s protocol. cDNA was generated using RevertAid First Strand cDNA 
Synthesis Kit (Fermentas). PCR reaction was performed using ABsoluteblue SYBR Green 
(Thermo Scientific) in StepOnePlus (Applied Biosystem) or CFX96 (Biorad) instruments. 
Beta-Actin gene was used as an endogenous control and the expression data was analyzed 
using the relative quantification method 2-ΔΔCt. Primer sequences are detailed in Table S3.
Western Blot—Livers were collected and snap frozen in liquid nitrogen. Tissue was lysed 
in tissue lysis buffer with phosphatase inhibitors (7M Urea, 0.5% Triton X-100, 150 mM 
NaCl, 10mM TrisHCl pH7.4, 1 mM EDTA, 1mM EGTA, 2mM Vanadate, 10mM NaF, 
2.5mM Sodium Pyrophosphate, proteinase inhibitor cocktail pill (Roshe Diagnostics). For 
PPARα immunoblots an additional step of nuclear extraction was first performed using the 
REAP method (Suzuki et al., 2010). Lysates were centrifuged and protein concentration was 
determined by Bradford protein assay (Biorad). 15ug protein were denatured at 100°C for 10 
minutes in Laemmli sample buffer then loaded onto a 10% Tris-glycine polyacrylamide gel 
and subjected to SDS-PAGE electrophoresis. Gels were transferred to nitrocellulose 
membranes (Biorad) using the Bio-Rad semidry transfer and blocked for 1 hour in filtered 
5% BSA. Immunoblotting was carried out with the following antibodies in 5% filtered BSA: 
SIRT6 (Cell Signaling), αTubulin (Sigma-Aldrich), Flag (Sigma), PDK4 (kindly donated by 
Robert Harris), PDH-E1a(pSer293) (Millipore), PDH-E1α (sc-377092), GFP and GST 
(Santa Cruz), and HRP-conjugated secondary antibodies mouse or rabbit (Jackson). Results 
were quantified with ImageJ.
ChIP—This protocol was adapted from Ram et al. (2011). 100mg frozen liver were 
homogenized using plastic disposable homogenizing pestles in cold PBS, the final volumen 
filtered through a 70uM filter with a 20 g needle to create a liver cell suspension in 10ml 
PBS. Cells were then crosslinked in 1% formaldehyde for 10 minutes at 37 degrees with 
gentle agitation then quenched with 5% glycine for 5 minutes at 37 degrees with gentle 
agitation. Cells were then washed x2 in PBS then lysed in nuclear extraction buffer (0.1% 
NP40-PBS) using REAP method (Suzuki et al., 2010). Nuclei were then lysed in chip lysis 
buffer (1% SDS, 50mM Tris-HCL pH 8.0, 10mM EDTA) containing protease inhibitors 
(Roche). Chromatin was sonicated using covaris S220 at 4°C (165 peak power, 10 duty 
factor, 200 cycles/burst, 6 minutes) to obtain 150–300bp DNA fragments. Chromatin lysate 
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was then precleared using prewashed 40ul protein A Dynabeads for 4 hours; in parallel 5ug 
of SIRT6 (AB-ab62739) or IGG (CS-#2729) antibody were conjugated to 50ul protein A 
Dynabeads for 4 hours according to manufacturer’s instructions using 250ul blocking buffer 
(PBS with 0.5%Tween and 0.5% BSA). Beads were then washed and added to chromatin 
lysate overnight. After incubation beads were washed x6 with RIPA, x2 with RIPA-NaCl 
(500mM), x2 with LiCl (250mM LiCl, 10mM TE, 0.5% DOC, 0.5% NP-40), x2 with TE, 
and then eluted overnight at 65 degrees in elution buffer (0.5% SDS, 5mM EDTA, 300mM 
NaCl, 10mM Tris-Hcl pH 8.0). Following elution samples were treated with proteinase K at 
55 degrees for 2 hours. DNA was then purified using Agencourt AMPure XP beads 
(Beckman Coulter) according to manufacturer’s instructions and eluted in TE. DNA 
concentration was quantified by Qubit, and 3ul of each chip was used as template. Data was 
normalized to inputs.
Luciferase Reporter Assay—HEK293T cells were cotransfected using calcium 
phosphate transfection protocol in 6-well plates with SIRT6/SIRT6 H133Y and PPARα /
empty plasmid, along with firefly luciferase reporter vector containing PPREx3, and Renilla 
as transfection control. 48hr post-transfection cells were harvested and luciferase activities 
were measured using Dual Luciferase Reporter Assay System (Promega).
Immunoprecipitation
In Vitro: 4ug of SIRT6-Flag or BIP-Flag (negative control) were incubated with either 
PPARα-GST or GST (negative control) overnight at 4°C in IP binding buffer (buffer A) with 
gentle agitation with 50ul anti-Flag M2 affinity gel (Sigma), to immunoprecipitate the Flag-
tagged proteins. Flag beads were then briefly centrifuged then washed x4 with wash buffer 
(50mM Tris pH 8.0, 1% NP40, 150mM NaCl, 1mM MgCl2, 10% glycerol, and protease 
inhibitor (Roche)), followed by elution with 5ul of diluted Flagx3 peptide (Sigma) in 100ul 
lysis buffer peptide with strong agitation for 30 minutes, according to manufacturer’s 
instructions. Elutions were then boiled in sample buffer then run on SDS-page with 0.4ug 
(10%) total input and probed for both Flag and GST.
In Vivo: 293T cells overexpressing 7ug Flag-tagged plasmids in a 10cm plate were first 
washed with PBS then lysed in 700ul cell lysis buffer. Lysates were sonicated using Branson 
sonicator at 60% for 40 s twice, and protein concentration was measured using Bradford 
reagent (Biorad). 1–4mg of protein per IP was then treated with 300 mg/ml ethidium 
bromide (EtBr) for 30 min on ice, followed by 10 min centrifugation at 17,000 g twice. 
Supernatants were subjected to immunoprecipitation with 50ul anti-Flag M2 affinity gel 
(Sigma) overnight at 4°C with gentle agitation to immunoprecipitate Flag-tagged proteins. 
Flag beads were then briefly centrifuged then washed 4 times with cell lysis buffer, followed 
by elution with 5ul of diluted flag peptide /in 100ul lysis buffer Flagx3 peptide (Sigma) with 
strong agitation for 30 minutes according to manufacturer’s instructions. Elutions were then 
boiled in sample buffer then run on SDS-page with 50ug (5%) total input and probed for 
both Flag and GFP or endogenous SIRT6.
ExpressionBlast Microarray Comparison Analysis—DE genes from RNA-seq WT 
versus HZ control treatment (0.5% carboxymethylcellulose) from Table S1B were submitted 
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into ExpressionBlast (https://bio.tools/expressionblast) with parameters: Input/output species 
Mus musculus, list of genes provided as gene symbol with fold change, distance function 
Euclidian, p val cutoff 0.01, count cutoff 20, % genes required to match: 65%, GO p val 
cutoff: 0.05. Euclidian function parameters were 3, 0.4, and 1.5 for trim expression values, 
magnitude weight, and sign penalty, respectively. Results were downloaded on 09/13/18 and 
are shown in Table S2. Categories for genes such as PPARα and GNMT had to include the 
word “PPARα” or “GNMT” in the GSM description or comparison (highlighted in red or 
blue in Table S2), and were manually examined to ensure the experiment was indeed a 
matching PPARα comparison. Other categories such (i.e., infection/cancer) were curated 
and manually validated in a similar manner. All key words for category determination are 
highlighted in blue in Table S2.
Respiratory Exchange Ratio (RER)—Mice were individually housed in metabolic 
chambers at room temperature (23°C) and allowed to acclimate for 3 days. Spontaneous 
movement, food and water consumption were continuously measured using automated 
indirect calorimetry (TSE Systems GmbH). After acclimation mice were gavaged daily with 
WY (50mg/kg) for 3 days, and then measured for an additional day without treatment. 
Oxygen consumption (VO2), carbon dioxide production (VCO2), and respiratory exchange 
ratio (RER) were measured every half hour.
Body Composition—Body composition was measured using quantitative nuclear 
magnetic resonance (NMR) using the Minispec LF90 (Bruker Optics, Billerica, MA). For 
liver composition, whole livers were dissected from mice and measured in the machine. Fat 
and Lean mass were recorded and percentages were calculated accordingly.
Metabolomics
Wy-Treated Mice: Mice were orally gavaged with WY or vehicle control (0.5% 
carboxymethylcellulose). Twelve hours later, mice were sacrificed by CO2 and livers were 
harvested and flash frozen. 50 mg of frozen liver tissue was pulverized and then 
homogenized in 50% aqueous acetonitrile containing 0.3% formic acid. Pyruvate, lactate, 
and alanine were measured as described (Jensen et al., 2006). Acetylcarnitine (C2) was 
measured as previously reported (Kusama et al., 2006; Wu et al., 2004).
Starved Mice: To maximize accuracy and to take into account tissue inhomogeneity, 
metabolites were extracted from 3 separate liver pieces for each mouse. Precellys Lysing 
Kits comprising prefilled tubes with beads (CK14 homogenizing tubes for soft tissue 
containing 1.4 mm ceramic beads) were prefilled with 1000ul of cold (−20°C) metabolites 
extraction solvent (MeOH:ACN:H20, 5:3:2) and kept on ice. Frozen tissue was cut, weighed 
and approximately 30 mg sample was added to the prefilled homogenization tube. Samples 
were homogenized at 4°C in a Precellys 24 homogenizer. (Homogenization at 3*20 s, 6000 
rpm with a 30 s gap between each of the three cycles). Homogenized samples were 
centrifuged in the Precellys tubes at 18,000 g for 15 min at 0–4°C. The supernatant was 
collected in a microcentrifuge tube and centrifuged again. The supernatants were transferred 
to glass HPLC vials and kept at −75°C prior to LC-MS analysis.
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LC-MS metabolomics analysis was performed as described previously (Mackay et al., 
2015). Briefly, Thermo Ultimate 3000 high-performance liquid chromatography (HPLC) 
system coupled to Q- Exactive Orbitrap Mass Spectrometer (Thermo Fisher Scientific) was 
used with a resolution of 35,000 at 200 mass/charge ratio (m/z), electrospray ionization, and 
polarity switching mode to enable both positive and negative ions across a mass range of 67 
to 1000 m/z. HPLC setup consisted ZIC-pHILIC column (SeQuant; 150 mm × 2.1 mm, 5 
μm; Merck), with a ZIC-pHILIC guard column (SeQuant; 20 mm × 2.1 mm). 5 ul of 
Biological extracts were injected and the compounds were separated with mobile phase 
gradient of 15 min, starting at 20% aqueous (20 mM ammonium carbonate adjusted to pH 
9.2 with 0.1% of 25% ammonium hydroxide) and 80% organic (acetonitrile) and terminated 
with 20% acetonitrile. Flow rate and column temperature were maintained at 0.2 ml/min and 
45°C, respectively, for a total run time of 27 min. All metabolites were detected using mass 
accuracy below 5 ppm. Thermo Xcalibur was used for data acquisition
TraceFinder 4.1 was used for analysis. Peak areas of metabolites were determined by using 
the exact mass of the singly charged ions. The retention time of metabolites was 
predetermined on the pHILIC column by analyzing an in-house mass spectrometry 
metabolite library that was built by running commercially available standards. Data from 
each sample was normalized to its corresponding tissue weight.
Fatty Acid Oxidation: Mice were orally gavaged with WY or vehicle control (0.5% 
carboxymethylcellulose). Twelve hours later, mice were sacrificed by CO2 and livers were 
harvested for fatty acid oxidation measurements. Freshly harvested liver samples were 
homogenized in ice cold 0.25 M sucrose, 10 mM Tris-HCl, 1 mM EDTA, at a pH of 7.4 
using a Dounce homogenizer. The homogenates were then centrifuged at 420 g for 10 
minutes to remove nuclear proteins and cell debris. The supernatant was then subjected to 
fatty acid oxidation measurements using 14C-palmitate as described in detail by Huynh et al. 
(2014).
RNA-Seq and Analysis: RNA was isolated with Trizol (Sigma). RNA quality was evaluated 
by Tapestation RNA Assay (Agilent Technologies, CA, USA). Libraries were constructed 
with the NEBNext Ultra RNA library prep Kit (#E7530, NEB) using manufacturer’s 
instructions. Final quality was evaluated by Tapestation DNA HS Assay (Agilent 
Technologies, CA, USA). Equimolar pooling of libraries were performed based on Qubit 
values and loaded onto an Illumina Hiseq 2500 platform (Illumina, CA, USA). These 
libraries were sequenced in multiplex as single-end non-strand specific 56-bp/61-bp reads on 
2 lanes of an Illumina HiSeq 2000, resulting in on average 28 million reads per sample.
The RNA sequencing data was aligned using STAR (v 2.5.0a) (Dobin et al., 2013) with 
default parameters. The UCSC mm10 iGenome build and its corresponding gtf were used to 
build the STAR reference database. The number of reads per gene were quantified using 
HTSeq-Count (v0.6.1p1) (Anders et al., 2015). The R Bioconductor package, DESeq2 
(v1.18.1) (Love et al., 2014), was used to classify genes as differentially expressed 
(Benjamini-Hochberg adjusted p value < 0.1). Reference genome and index used:ftp://
igenome:G3nom3s4u@ussd-ftp.illumina.com/Mus_musculus/UCSC/mm10/
Mus_musculus_UCSC_mm10.tar.gz.
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Ingenuity Analysis: The networks, pathways, and regulators functional analyses were 
generated through the use of IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/
products/ingenuity-pathway-analysis). Networks were customized in Ingenuity by 
modifying font and text size, and bolding genes of interest, but were otherwise left intact.
Microfluidics Protein-DNA Interaction: Protein-DNA interactions were carried out as 
previously described (Glick et al., 2016b). In each experiment, 25 mL of extract (50 ng of 
protein) was loaded into the device. Introduction of 3′-HIS&5′-cMyc or Flag-tagged TFs 
complex into the DNA chambers solubilize spotted DNA, allowing TFs and DNA to 
interact. TF-DNA complexes were then captured on the chip surface beneath the ‘button’ 
valve during a 1 hour incubation period at 32°C. Next, MITOMI was performed by closing 
the ‘button’ valve to trap the interactions. Protein complexes and DNA not trapped by 
MITOMI were then washed away. TFs were labeled with α-FLAG cy3 (Sigma). Proteins 
expression levels and interacting DNA signals were measured with a microarray scanner (LS 
Reloaded, Tecan) using a 488 nm laser and 535 filter for Cy3, and a 633 nm laser and 695 
nm filter for Cy5. Cy3 intensities under the ‘button’ valve reflect the number of surface-
bound protein molecules; Cy5 intensities under the ‘button’ valve reflect the number of 
DNA molecules bound by surface-immobilized protein. The ratio of Cy5 to Cy3 
fluorescence is proportional to the number of DNA molecules bound per protein, namely, 
protein fractional occupancy. Cy5 intensities within the DNA chamber reflect the amount of 
soluble DNA available for binding.
PPRE and Mutant Sequence Mini-library Preparation: PPRE\mutant elements from Oka 
et al. (2012) were prepared as previously reported (Glick et al., 2016a). DNA primers were 
synthesized (IDT), hybridized to a Cy5-labeled primer and extended using Klenow fragment 
(exo-) (New England Biolabs) to produce Cy5-labeled dsDNA. Cy5-labeled dsDNA 
oligonucleotides were diluted to a final concentration of 2 μM then serially diluted in 32 
dilutions ranging from 2 μM down to 0.0156 μM. Each sample contained 0.125% Poly 
ethylene glycol (Peg, Sigma-Aldrich) and 1.25 mg/ml D-trehalose dihydrate (Sigma-
Aldrich) in dH2O, preventing irreversible binding of the DNA to the printed slide as well as 
for visualization during alignment of the device to the DNA array. A negative control sample 
with no DNA was included. The oligonucleotides were spotted onto epoxy coated glass 
substrates (CEL Associates) with a MicroGrid 610 (Bio Robotics) microarrayer using SMT-
S75 silicone pins (Parallel Synthesis, USA). Column and row pitch corresponded to the 
specific device. The microfluidic device that was used contains 64 columns and 64 rows 
with a pitch of 280 μm by 560 μm, respectively.
Microfluidics Protein-Protein Interaction: Protein-protein interactions on chip were 
carried out as previously described (Gerber et al., 2009). Human proteins (C-TIP, PPARα 
and HIF1α) with N terminus c-Myc and C terminus His tags were expressed by using rabbit 
reticulocyte quick-coupled TNT reaction (Promega). Surface chemistry was prepared and α-
HIS biotinylated antibodies (QIAGEN) were bound under buttons on chip. Next, each 
expressed protein was attached to a specific part of the device and bound to its 
corresponding antibody. Finally, Flag-tagged SIRT6 was applied to the device. By closing 
the sandwich valves, each unit cell separated from its environment. SIRT6 were allowed to 
Naiman et al. Page 20
Cell Rep. Author manuscript; available in PMC 2020 April 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
incubate with the proteins for 30 min at 32°C. Next, the button valves opened, exposing 
proteins, and unbound protein was washed away. Bound proteins were then labeled with α-
c-Myc Alexa Fluor 647 (Abcam) and α-FLAG cy3 (Sigma) antibodies. Protein interactions 
were determined with a microarray scanner (LS Reloaded; Tecan) using a 633-nm laser and 
695-nm filter for Alexa Fluor 647 and a 535-nm laser and 595-nm filter for Cy3.
Microscale Thermophoresis Binding Assay (MST): Fluorescent labeled HIS-tagged 
human SIRT6 was incubated with increasing concentrations of ADP-ribose or WY-14643 
for 30 min at room temperature (RT) in MST assay buffer ((50 [mM] Tris-HCl pH = 8.0, 
137 [mM] NaCl, 2.7 [mM] KCl, 1[mM] DTT and 1[mM] MgCl2 0.1% Tween).)prior to 
MST measurements in order to achieve thermodynamic equilibrium. The samples loaded 
into premium coated capillaries (NanoTemper Technologies). Measurements were 
conducted with 20% LED power and 20% of MST power (IR laser intensity) for ADP-
ribose or 40% for WY-14643. Initial florescence was measured in order to dismiss 
fluorescence quenching and protein adhesion to the capillary surface. Data was fitted and 
analyzed using the MST analysis software.
Fluorescent Deacylation Assay (F.D.): The assay is based on 7-amino-4-methylcoumarin 
(AMC) fluorophore, attached to a myristoylated peptide substrate (H3-K(Myristoyl)-AMC) 
(Peptron Inc). The procedure requires 3 steps in F.D. assay buffer (50 mM Tris-HCl pH = 
8.0, 137 mM NaCl, 2.7 mM KCl, 1[mM] DTT and 1mM MgCl2). In the first step, 50 μM 
WY-14643 or DMSO control were incubated with 0.5 μM human recombinant SIRT6 along 
with NAD+ (100μM) and H3-K(Myristoyl)-AMC (50μM) at 37°C for 60 min in a reaction 
tube. Upon demyristylation, the peptide becomes a trypsin substrate. In the next step, 
samples at time 0 and 60 min were taken and quenched with SIRT6 inhibitor nicotinamide 
(NAM, 20mM) in a 96-well black plate (Perkin Elmer). Next, treatment with trypsin from 
bovine pancreas (sigma) at 25° for 30 min released the fluorophore and fluorescence 
intensity was measured (excitation: 370nm and emission 440nm). The plate containing the 
incubations was read using SYNERGY4 microplate reader. Increase in fluorescent intensity 
indicates reaction progression. For analysis, fluorescent intensities at time 0 were subtracted 
from time 60 min.
QUANTIFICATION AND STATISTICAL ANALYSIS
All data are expressed as mean ± SEM. For single comparisons with one condition, 
significance was calculated between groups using a two-tailed unpaired Student’s t test. For 
experiments with 2 factors (i.e., treatment and genotype) a 2-way ANOVA followed by 
Tukey post hoc was used. For experiments with multiple comparisons with one factor a one-
way ANOVA with Bonferroni post hoc was used. Area under curve (AUC) for RER was 
measured from 7AM to 7PM for each day. In all experiments p < 0.05 was considered 
significant. For RNA-Seq experiments FDR q < 0.1 was deemed significant. All analyses 
were performed using Graphpad Prism 8 (GraphPad, San Diego, CA). Statistical parameters 
and information on biological replicates (n) are indicated in the figure legends. Statistically 
significant differences are indicated as * p < 0.05, **p < 0.01. Ns indicates not significant 
differences. Animals were randomized to treatment groups and treated blinded to genotype. 
Measurements were performed blinded to treatment or genotype.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• PPARα mediates various SIRT6-regulated metabolic pathways
• PPARα binds to and is activated by SIRT6 to promote fatty acid beta 
oxidation
• SIRT6 decreases NCOA2 acetylation and induces its coactivation of PPARα
• Coordinated SIRT6-PPARα activities control energy production under limited 
nutrients
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Figure 1. SIRT6 Deficiency Inhibits PPARα Signaling Gene Expression
(A) Heatmap of top-20 up and down differentially expressed (DE) genes in RNA-seq of 
SIRT6 HZ mice.
(B) Quantitative real-time PCR analysis of mouse mRNA levels of 5 up- and down-regulated 
genes from the RNA-seq.
(C) Ingenuity pathway analysis (IPA).
(D) Ingenuity regulator analysis of DE genes.
(E) PPARα inhibitory gene network.
(F) Lipid metabolism network of DE genes.
(G) ExpressionBlast analysis of top-20 microarray comparison matches to SIRT6 HZ DE 
genes.
In (A)–(G), n = 7 mice per genotype. In (A) DESeq2 with false discovery rate (FDR) < 0.1 
and a fold change cutoff > 1.5 were used to find DE genes. In (B), data are represented as 
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means + SE; *p < 0.05, significance was calculated by two-tailed Student’s t test. In (C)–(F), 
IPA was used to calculate significant pathways, regulators, and networks. In (G), 
ExpressionBlast was used to calculate significant expression matches; *p < 0.01.
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Figure 2. SIRT6 Directly Interacts with PPARα and Binds to and Activates the PPRE In Vivo
(A) In vitro pulldown assay of SIRT6-FLAG and co-immunoprecipitation of GST-PPARα 
from recombinant proteins.
(B) Microfluidics in vitro association assay. SIRT6-FLAG was fixed onto the chip, and Myc-
tagged associated proteins were incubated and then washed. Interaction ratio was detected 
by fluorescence (left). Representative fluorescence binding on chip (right).
(C) Co-immunoprecipitation of FLAG-tagged SIRT6 and GFP-tagged PPARα.
(D) Co-immunoprecipitation of FLAG-tagged PPARα and endogenous SIRT6 from 
HEK293T cells.
(E) Microfluidics assay of SIRT6 binding to PPRE or mutant sequence in the presence/
absence of PPARα and representative fluorescence binding on chip.
(F) Luciferase activity of PPRE promoter in HEK293T cells overexpressing either SIRT6 
WT or dominant-negative (DN) mutant.
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(G) Luciferase activity in HEK293T cells overexpressing SIRT6 and increasing amounts of 
PPARα.
(H) Srebp2 and Gapdh were used as positive/negative controls, respectively.
(I) ChIP-quantitative real-time PCR analysis of H3K9 acetylation on PPREs of indicated 
genes in WT and Sirt6+/− livers.
In (B), data are represented as means + SE and significance was calculated by one-way 
ANOVA followed by a Bonferroni multiple comparisons test; n = 10. In (E)–(I), data are 
represented as means + SE. In (E) and (I), two-way ANOVA followed by a Bonferroni 
multiple comparisons test were used; n = 10 for (A) and (E) and n = 3 for (I). In (H), 
significance was calculated by two-tailed Student’s t test. *p < 0.05, **p < 0.01.
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Figure 3. SIRT6 Stimulates WY-Induced PPARα Transcriptional Activity In Vivo
(A–D) Quantitative real-time PCR analysis of mouse mRNA levels of PPARα target genes 
from specified pathways in WT and SIRT6 HZ (A), and SIRT6 TG (B) control and WY-
treated primary hepatocytes. Quantitative real-time PCR analysis of mouse mRNA levels of 
PPARα target genes from specified pathways in WT and SIRT6 HZ (C), and SIRT6 TG (D) 
control and WY-gavaged mice. Genes are categorized into different pathways as labeled 
above.
In (A)–(D), data are represented as means + SE; *p < 0.05, calculated by two-tailed 
Student’s t test; n = 7 per genotype.
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Figure 4. SIRT6 Deficiency Inhibits PPARα-Regulated Metabolic Pathways
(A) Scheme depicting SIRT6 regulation of metabolic pathways via PPARα.
(B) Western blot analysis of pyruvate oxidation signaling following WY treatment (50 
mg/kg) (left) in WT mice, and in WT versus HZ WY-treated mice (middle), and ImageJ 
quantification (right). Tubulin was used as loading control and CMC 0.1% was used as 
control for the WY.
(C) β-oxidation pathway measurements including quantitative real-time PCR analysis of 
mRNA levels of fatty acid transporter Cd36 (left), metabolite acetylcarnitine C2 (middle), 
and CO2 levels from 14C-labeled palmitate in mitochondria (right) from WY-treated control 
and SIRT6 HZ livers.
(D) Quantitative real-time PCR analysis of mRNA levels of glycerol transporter Aqp3.
(E) Gluconeogenic precursor metabolites lactate (left) and amino acid alanine (right).
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(F) Quantitative real-time PCR analysis of mRNA levels of glycogenolysis and glycogen 
synthesis enzymes Pygl and Gys2, respectively. In (B)–(F), all from livers of WT and HZ 
mice following control (CMC) or WY treatment.
(G and H) Metabolites (G) and quantitative real-time PCR analysis of mRNA levels in livers 
of fasted WT and SIRT6 TG mice (H).
In (B)–(H) proteins and genes are represented as means + SE and metabolites are 
represented as means + max/min; *p < 0.05, **p < 0.01. In (B), (G), and (H) a two-tail 
Student’s t test was used; n = 6–7 per genotype. In (C)–(F), two-way ANOVA followed by a 
Bonferroni multiple comparisons test were used; n = 6–7 per genotype.
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Figure 5. SIRT6 Regulation of Pyruvate and b-oxidation Is PPARα Dependent
(A) PPARα protein expression levels in nuclear fractions of primary hepatocytes 
overexpressing either scrambled siRNA control or two different PPARα siRNAs. Histone 
H3 was used as loading control. ImageJ quantification of PPARα levels is shown on the 
right.
(B) Luciferase activity of PPRE in WT or SIRT6 overexpressing Hepa1–6 mouse 
hepatocytes overexpressing either scrambled siRNA control or two different PPARα siRNAs 
with or without WY treatment.
(C) Quantitative real-time PCR analysis of mouse mRNA levels of PPARα target genes from 
specified pathways in WT and SIRT6 overexpression (OE) primary hepatocytes 
overexpressing either scrambled siRNA control or two different PPARα siRNAs with or 
without WY treatment.
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(D) Western blot analysis of pyruvate oxidation signaling following WY treatment in WT 
mice and SIRT6 OE primary hepatocytes overexpressing either scrambled siRNA control 
(labeled as c) or two different PPARα siRNAs (left). PDK4/Tubulin and pPDC/PDC were 
quantified by ImageJ (right). Tubulin was used as loading control.
In (A)–(D), data are represented as means + SE; *p < 0.05, **p < 0.01. In (A), one-way 
Anova was used to calculate significance followed by a Bonferroni multiple comparisons 
test, n = 2 per genotype. In (B) and (C), significance was calculated by two-way ANOVA 
followed by a Bonferroni multiple comparisons test; n = 2 per genotype. In (D), significance 
was calculated by two-tailed Student’s t test; n = 2 per genotype.
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Figure 6. SIRT6 Increases Hepatic Fat Loss and Improved RER via PPARα
(A) Heatmap of top-20 up and down differentially expressed (DE) genes in RNA-seq of 
livers of WY-treated SIRT6 HZ mice.
(B and C) Ingenuity regulator analysis (B) and IPA (C) of DE genes in WY-treated SIRT6 
HZ mice.
(D) Integrated PPARα-activated and SREBP1/2-inhibited overlapping gene network. The 
pound sign (#) indicates genes validated by quantitative real-time PCR analysis.
(E) Quantitative real-time PCR analysis of mRNA levels of PPARα-dependent SREBP 
cholesterol and triglyceride synthesis genes from (D).
(F and G) NMR measurements of total fat content in livers of WY-treated SIRT6 TG (F) and 
SIRT6 HZ (G) mice, in both grams and normalized to total liver weight.
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(H) Respiratory exchange ratio (RER) of WT or HZ mice given daily WY treatment. Black 
arrows indicate time of WY treatment (left). AUC, area under curve for average 3 days of 
treatment (right); arrow indicates start of treatment.
In (A), DESeq2 with FDR < 0.1, fold change > 1.5 was used to find DE genes, n = 7. In (B)–
(D), IPA was used to calculate significant pathways, regulators, and networks, n = 7. In (E)–
(H), data are represented as means + SE. In (E)–(G), *p < 0.05, significance calculated by 
two-way ANOVA followed by a Bonferroni multiple comparisons test; n = 5–8 per 
genotype. In (H), AUC was calculated using Prism followed by two-tailed Student’s t test; n 
= 3 per genotype.
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Figure 7. SIRT6 Regulates PPARα Activity via NCOA2 K780 Deacetylation
(A) MS quantification of acetylated levels of various PPARα co-activators/repressors in WT 
and SIRT6 OE mouse liver.
(B) Luciferase activity of PPRE in WT- or SIRT6-overexpressing HEK293T cells 
overexpressing either empty plasmid control or NCOA2 WT, K780Q, and K780R with or 
without PPARα overexpression.
(C) Co-immunoprecipitation of FLAG-tagged SIRT6 and endogenous NCOA2 (top) or 
FLAG-tagged NCOA2 and endogenous SIRT6 (bottom).
(D) Schematic representation of SIRT6 regulation of PPARα via NCOA2 deacetylation 
under conditions in which is PPARα activated.
In (A) and (B), data are represented as means + SE. In (A), FDR q < 0.1 was deemed 
significant, n = 3 per genotype. In (B), significance was calculated by two-way ANOVA 
followed by a Bonferroni multiple comparisons test; *p < 0.05, n = 7 per genotype.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit monoclonal anti-SIRT6 (clone 
D8D12) Cell Signaling Technology Cat# 12486; RRID: AB_2636969
Mouse monoclonal anti-Flag (clone M2) Sigma-Aldrich Cat# F3165; RRID:AB_259529
Mouse monoclonal anti-GST (clone B-14) Santa Cruz Biotechnology Cat# sc-138; RRID: AB_627677
Mouse monoclonal anti-GFP (clones 7.1 
and 13.1) Roche Cat# 11814460001; RRID: AB_390913
Mouse monoclonal anti-PPARA (clone H-2) Santa Cruz Biotechnology Cat# sc-398394
Mouse monoclonal anti-Flag-Cy3 (clone 
M2) Sigma-Aldrich Cat# A9594; RRID: AB_439700
Rabbit polyclonal anti-c-Myc-Cy5 Bioss Cat# bs-0842R-Cy5; RRID: AB_11049406
Mouse monoclonal anti-Cy5 (clone CY5–
15) Sigma-Aldrich Cat# C1117; RRID: AB_477654
Rabbit polyclonal anti-PDK4 Jeoung et al., 2006 N/A (Custom-produced by Sigma-Genosys)
Rabbit polyclonal anti-phospho-PDH-E1α 
(Ser293) Millipore Cat# AP1062; RRID: AB_10616069
Mouse monoclonal anti-PDH-E1α (clone 
D-6) Santa Cruz Biotechnology Cat# sc-377092; RRID: AB_2716767
Mouse monoclonal anti-alpha-Tubulin 
(clone B512) Sigma-Aldrich Cat# T5168; RRID: AB_477579
Rabbit polyclonal anti-PPARA Santa Cruz Biotechnology Cat# sc-9000; RRID: AB_2165737
Rabbit polyclonal anti-phospho-AMPk 
(Thr172) Cell Signaling Technology Cat# 2531; RRID: AB_330330
Rabbit monoclonal anti-AMPK (clone 
D5A2) Cell Signaling Technology Cat# 5831; RRID: AB_10622186
Rabbit polyclonal anti-SREBP2 Abcam Cat# ab30682; RRID: AB_779079
Rabbit polyclonal anti-H3 Abcam Cat# ab39655; RRID:AB_732921
Rabbit polyclonal anti-H3K9 Abcam Cat# ab4441; RRID:AB_2118292
Bacterial Strains
Escherichia coli Bl21 (De3) strain New England Biolabs Cat# C2527
Escherichia coli Dh5a strain Invitrogen Cat# 18263012
Chemicals, Peptides, and Recombinant Proteins
WY 14643 AbMole Cat# M1880
Ethidium Bromide Sigma-Aldrich Cat# E1510
Carboxymethylcellulose sodium salt Sigma-Aldrich Cat# C4888
Formaldehyde 37% Sigma-Aldrich Cat# F1635
Collagen Santa Cruz Cat# SC-136157
Liver digest medium Thermo Fisher Scientific Cat# 17703034
Human Insulin solution Santa Cruz Cat# SC-360248
Dexamethasone Sigma-Aldrich Cat# D2915
DMSO Sigma-Aldrich Cat# D4540
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REAGENT or RESOURCE SOURCE IDENTIFIER
HBSSx10 GIBCO Cat# 14185045
Sodium Pyruvate Invitrogen Cat# 11360–070
Percoll Sigma-Aldrich Cat# P1644
EDTA Santa Cruz Cat# SC-29092
Dynabeads Protein G Thermo Fisher Scientific Cat# 10003D
Medium199 Invitrogen Cat# 11150–059
Proteinase K Roche Cat# 3115879001
TriReagent Sigma-Aldrich Cat# 93289
Lipofectamine 2000 Thermo Fisher Scientific Cat# 11668027
Lipofectamine RNAiMAX Thermo Fisher Scientific Cat# 13778075
Flag×3 Peptide Sigma-Aldrich Cat# F4799
Critical Commercial Assays
ANTI-FLAG® M2 Affinity Gel Sigma-Aldrich Cat# A2220
GFP-Trap Agarose Chromotek Cat# gta200
RevertAid First Strand cDNA Synthesis Kit Thermo Fisher Scientific Cat# K1621
Agencourt AMPure XP kit Beckman Coulter Cat# A63881
NEBNext® Multiplex Oligos for Illumina New England Biolabs Cat# E7335
Qubit dsDNA HS Assay Kit Invitrogen Cat# Q32851
NEBNext® Ultra DNA Library Prep Kit for 
Illumina New England Biolabs Cat# E7370
NextSeq 500/550 High Output Kit v2.5 Ilumina Cat# 20024906
Deposited Data
Raw and analyzed RNA sequencing data This paper GEO: GSE140063
Mus musculus genome build 38 
GRCm38.p6 Ensembl Mus_musculus.GRCm38.dna.primary_assembly.fa
Experimental Models: Cell Lines
Human HEK293T ATCC Cat. # CRL-11268; RRID:CVCL_0063
Mouse Hepa1–6 ATCC Cat# CRL-1830, RRID:CVCL_0327
Mouse AML12 ATCC Cat# CRL-2254, RRID:CVCL_0140
Experimental Models: Organisms/Strains
C57B-SIRT6-TG (SIRT6 Overexpression) Kanfi et. al., 2012 Cohen Lab
CB6-SIRT6-TG (SIRT6 Overexpression) Kanfi et. al., 2012 Cohen Lab
129-Sirt6tm1Fwa/J (SIRT6 Heterozygote) The Jackson Laboratory Kind gift from Dr. Raul Mostoslavsky
Oligonucleotides
Oligonucleotides for Chip This paper Table S3, tab A
Oligonucleotides for qRT-PCR This paper Table S3, tab B
TriFECTA RNAi Kit for PPARA mouse IDT mm.Ri.Ppara.13
Recombinant DNA
pSG5-Ncoa2-Flag Ogawa et. al., 2004 Kind gift from Dr. Hidesato Ogawa
pSG5-Ncoa2 Leers et. al., 1998 Kind gift from Dr. Hinrich Gronemeyer
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REAGENT or RESOURCE SOURCE IDENTIFIER
pCDNA3.1+-Ncoa2-Flag This paper N/A
pCDNA3.1+-Ncoa2K780Q-Flag This paper N/A
pCDNA3.1+-Ncoa2K780R-Flag This paper N/A
pCAGGS-SIRT6 This paper N/A
pCAGGS-SIRT6-H133Y This paper N/A
pCDNA3.1+-SIRT6-Flag Gil et. al, 2013 N/A
pCDNA-PPARA-GFP This paper N/A
pGEX4t3-GST-PPARA This paper N/A
pET28a-His-PPARA This paper N/A
pET28a-SIRT6-Flag Gil et. al, 2013 N/A
Software and Algorithms
ImageJ Version 1.8 Schneider et al., 2012 https://imagej.nih.gov/ij
Bowtie2 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/bowtie2/index.Shtml
Samtools Li et al., 2009 http://samtools.sourceforge.net/
STAR 2.6 Dobin and Gingeras, 2015 https://github.com/alexdobin/STAR
MarkDuplicates tool in picard-tools-1.8.4 Broad Institute http://broadinstitute.github.io/picard/
R (version 3.2.3) The R Foundation https://www.r-project.org/
R Studio The R Foundation https://rstudio.com/
DESeq2 (version 1.10) Love et al., 2014 https://bioconductor.org/packages/release/bioc/html/DESeq2.html
GraphPad Prism (version 8.0 for Windows) GraphPad https://www.graphpad.com/scientific-software/prism/
Ggplot2 Hadley Wickham https://ggplot2.tidyverse.org/
Ingenuity Pathway Analysis QIAGEN https://www.ingenuity.com
Other
Multi channel cassette pump Watson Marlow Cat# 205CA
C96 MicroWellTM Plates Thermo Fisher Scientific Cat# 437796
70 μm cell strainer Corning Cat# CLS431751
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